Home/Filings/4/A/0001842952-21-000027
4/A//SEC Filing

Lehr Martin A. 4/A

Accession 0001842952-21-000027

CIK 0001842952other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:18 PM ET

Size

16.8 KB

Accession

0001842952-21-000027

Insider Transaction Report

Form 4/AAmended
Period: 2021-10-22
Lehr Martin A.
DirectorChief Executive Officer
Transactions
  • Conversion

    Series Seed Preferred Stock

    2021-10-22586,4751 total(indirect: By Trust)
    Common Stock (586,475 underlying)
  • Purchase

    Common Stock

    2021-10-22$5.00/sh+10,000$50,000807,190 total(indirect: By Trust)
  • Exercise Out-of-Money

    Warrant (right to buy)

    2021-10-22+52,6800 total(indirect: By Trust)
    Exercise: $7.14From: 2020-12-20Exp: 2030-12-20Common Stock (52,680 underlying)
  • Exercise Out-of-Money

    Common Stock

    2021-10-22$7.14/sh+52,680$376,1350 total(indirect: By Trust)
  • Conversion

    Common Stock

    2021-10-22+210,715210,715 total(indirect: By Trust)
  • Conversion

    Common Stock

    2021-10-22+586,475797,190 total(indirect: By Trust)
  • Conversion

    Series A Preferred Stock

    2021-10-22210,7157 total(indirect: By Trust)
    Common Stock (210,715 underlying)
Holdings
  • Common Stock

    89,583
Footnotes (3)
  • [F1]Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
  • [F2]Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
  • [F3]Fully vested.

Issuer

Context Therapeutics Inc.

CIK 0001842952

Entity typeother

Related Parties

1
  • filerCIK 0001861989

Filing Metadata

Form type
4/A
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:18 PM ET
Size
16.8 KB